British Prime Minister Boris Johnson, wearing a face mask to prevent the spread of the coronavirus, visits a pharmaceutical manufacturing facility during a visit to northeast England on February 13, 2021.

WPA pool | Getty Images News | Getty Images

LONDON – UK Prime Minister Boris Johnson said Wednesday he would receive the coronavirus vaccine developed by AstraZeneca and Oxford University as a clot safety clearance is underway in Europe.

Johnson informed UK lawmakers that he had received a call from the National Health Service launching the UK’s prestigious vaccination program to say he was now in line to get a shot and that he was going to Oxford -AstraZeneca vaccine is going to be received “very soon.”

“The best I can say about Oxford-AstraZeneca’s vaccination program is that I finally got the news that I will be getting my own sting shortly,” says Johnson, who is 56 years old and will catch coronavirus in the next age group Vaccine said Wednesday.

His comments come from an increasing number of European countries stop using the Oxford-AstraZeneca vaccine because of concerns that it could be linked to a low number of blood clots reported among people who have been vaccinated.

Germany, France, Italy, the Netherlands and Spain are among the European countries that have suspended the use of the shot.

The World Health Organization and the EU Medicines Agency, the European Medicines Agency, are conducting a review of the vaccine data but have recommended that you continue to use the vaccine during this review, saying that the benefits outweigh the risks.

On Wednesday, the WHO issued a statement saying that “vaccination against COVID-19 will not reduce disease or death from other causes”.

“It is known that thromboembolic events are common. Venous thromboembolism is the third most common cardiovascular disease worldwide,” it said.

A wave of precautionary suspensions

Health experts have commented that the decision to suspend the use of the shot is confusing at a time when much of Europe is facing spikes in infections due to more infectious variants of the virus, particularly as Europe relies on the Oxford-AstraZeneca vaccine for its immunization program as well as the shot from Pfizer-BioNTech.

For their part, both AstraZeneca and Oxford University have insisted that the vaccine is safe. AstraZeneca said in a statement Sunday that the number of blood clots recorded after vaccination was even fewer than would naturally be expected in the general population.

It is not the first time that Oxford-AstraZeneca’s vaccine has come under pressure, as the drug company was previously interviewed about its testing method and data.

Some European countries questioned the effectiveness of the shot in those over 65 (real data has since shown the vaccine to be highly effective in reducing severe Covid cases, hospitalizations, and deaths), and the pharmaceutical company had a well-publicized dispute with the EU on the delivery of supplies to the block.

With this in mind, some experts believe the vaccine suspension could be politically motivated.